Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tarsus Pharmaceuticals Inc (TARS)

Tarsus Pharmaceuticals Inc (TARS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,782,108
  • Shares Outstanding, K 42,449
  • Annual Sales, $ 182,950 K
  • Annual Income, $ -115,550 K
  • EBIT $ -87 M
  • EBITDA $ -90 M
  • 60-Month Beta 0.57
  • Price/Sales 7.29
  • Price/Cash Flow N/A
  • Price/Book 7.95

Options Overview Details

View History
  • Implied Volatility 71.83% (-4.79%)
  • Historical Volatility 39.31%
  • IV Percentile 85%
  • IV Rank 71.62%
  • IV High 85.25% on 02/24/25
  • IV Low 37.97% on 08/20/25
  • Expected Move (DTE 28) 9.00 (13.73%)
  • Put/Call Vol Ratio 2,039.00
  • Today's Volume 2,040
  • Volume Avg (30-Day) 121
  • Put/Call OI Ratio 0.55
  • Today's Open Interest 4,123
  • Open Int (30-Day) 3,996
  • Expected Range 56.54 to 74.54

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.19
  • Number of Estimates 3
  • High Estimate 0.07
  • Low Estimate -0.68
  • Prior Year -0.60
  • Growth Rate Est. (year over year) +68.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
60.54 +8.26%
on 02/13/26
73.82 -11.22%
on 01/22/26
-5.60 (-7.87%)
since 01/16/26
3-Month
60.54 +8.26%
on 02/13/26
85.25 -23.12%
on 12/09/25
-11.57 (-15.00%)
since 11/19/25
52-Week
38.51 +70.19%
on 08/01/25
85.25 -23.12%
on 12/09/25
+15.99 (+32.27%)
since 02/19/25

Most Recent Stories

More News
Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors

IRVINE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced the appointment of David E. I. Pyott, a distinguished leader in the global biopharmaceutical...

TARS : 65.54 (+3.59%)
Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026

IRVINE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Monday, February 23,...

TARS : 65.54 (+3.59%)
Tarsus to Participate in Upcoming Investor Conference

IRVINE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in a fireside chat at the BTIG 5 th Annual Ophthalmology...

TARS : 65.54 (+3.59%)
Tarsus to Participate in Upcoming Investor Conference

IRVINE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in a fireside chat at the Guggenheim 2 nd Annual Healthcare...

TARS : 65.54 (+3.59%)
Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements

Delivered quarterly  XDEMVY ® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter...

TARS : 65.54 (+3.59%)
Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Tuesday, November 4,...

TARS : 65.54 (+3.59%)
Bank of America Securities Remains a Buy on Tarsus Pharmaceuticals (TARS)

In a report released today, Jason Gerberry from Bank of America Securities maintained a Buy rating on Tarsus Pharmaceuticals, with a price target of $85.00. The company’s shares closed yesterday at $69.75.Elevate...

TARS : 65.54 (+3.59%)
Bank of America Securities Sticks to Its Buy Rating for Tarsus Pharmaceuticals (TARS)

In a report released today, Jason Gerberry from Bank of America Securities maintained a Buy rating on Tarsus Pharmaceuticals, with a price target of $80.00. The company’s shares closed yesterday at $58.77.Elevate...

TARS : 65.54 (+3.59%)
Tarsus to Participate in Upcoming Investor Conferences

IRVINE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences: ...

TARS : 65.54 (+3.59%)
3 Biotech Catalysts Present Major Opportunity

Three promising biotech names stand out for potentially catalyzing drugs currently on the market or in development; here's why they may rally further.

BSX : 75.72 (-0.73%)
TARS : 65.54 (+3.59%)
ARQT : 27.95 (+4.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Tarsus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutic candidates to address ophthalmic conditions. The company's product candidate consist TP-03 which is in clinical stage. Tarsus Pharmaceuticals Inc. is based...

See More

Key Turning Points

3rd Resistance Point 72.10
2nd Resistance Point 68.98
1st Resistance Point 67.26
Last Price 65.54
1st Support Level 62.42
2nd Support Level 59.30
3rd Support Level 57.58

See More

52-Week High 85.25
Fibonacci 61.8% 67.40
Last Price 65.54
Fibonacci 50% 61.88
Fibonacci 38.2% 56.36
52-Week Low 38.51

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar